RNA Formulation Videos

  1. In What Ways Are We Underestimating LNP Complexity Today? 12/4/2024

    As the RNA-LNP space continues to diversify beyond linear mRNA and infectious disease vaccines, Kate Zhang of Hopewell Therapeutics, Sumit Luthra of Sanofi, and Ben Muir of BioNTech each address several misconceptions about LNP composition today and how the rise of novel RNA modalities, more advanced mechanisms of action, and novel lipids are challenging our understanding of/work with LNPs today.

  2. What Does 2025 (And Beyond) Hold For The RNA-LNP Space? 12/4/2024

    Three LNP experts share their thoughts on the incremental advancements they’d like to see the RNA-LNP space make in the next few years.

  3. The Latest And Greatest Technological Innovations In mRNA-LNP Production 2/10/2025

    In this segment, Replicate Biosciences’ Andy Geall, Qian Ruan, & Alex Aust identify the most promising technological and raw material innovations that are influencing the drug substance and drug product production processes at CDMOs.

  4. Flexible Liquid Nanoparticle (LNP) Systems 12/6/2024

    From research and clinical studies to full-scale production, revolutionize your lipid nanoparticle (LNP) production with flexible and scalable solutions.

  5. Addressing Industry Challenges In mRNA Product Commercialization

    While the speed of production and flexibility of mRNA are appealing, several industry challenges must still be addressed to realize the full potential and further expand its use.

  6. The NanoAssemblr® Spark™ Robust Low Volume RNA-Lipid Nanoparticle Formulation 4/14/2022

    Develop RNA-lipid nanoparticles (LNPs) in under 10 seconds for drug discovery and early preclinical development. The NanoAssemblr®️ Spark™ instrument enables rapid µL formulations to conserve limited and expensive ingredients with minimal waste.

  7. Q&A On Formulation & Stability Of LNPs 11/28/2022

    Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, address audience questions around the importance of drug substance and drug product stability in efficient delivery in this segment of the Bioprocess Online Live! event LNPs & Beyond: Opportunities in RNA Delivery.

  8. Face- Phase-Off: Matching CDMO Capabilities To Your mRNA-LNP Development Stage 2/10/2025

    There are many different criteria for selecting a CDMO for your mRNA products. Arcturus’ Qian Ruan explains that a product’s stage of development and the specific needs inherent to that phase of development should be an important guide for companies today, especially given the expansion of the outsourcing sector and the wide range of capabilities.

  9. Achieving mRNA-LNP Delivery Beyond The Liver 11/28/2022

    In this segment, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, discuss which ongoing industry efforts to improve LNPs and the RNA/mRNA cargo they're watching closely that could help the RNA industry move beyond hepatic delivery.

  10. How To Successfully Control The Upscaling Of Your LNP Formulation 5/28/2025

    Discover key strategies for controlling LNP formulation and upscaling. Explore the science behind lipid nanoparticles, critical parameters, and achieving effective turbulent mixing for optimal outcomes.